PROCEPT BioRobotics (PRCT) Financials

$25.07 -0.11 (-0.44%)

As of 10:50 AM Eastern

Annual Income Statements for PROCEPT BioRobotics

This table shows PROCEPT BioRobotics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-53	-60	-87	-106	-91	-96
Consolidated Net Income / (Loss)	-53	-60	-87	-106	-91	-96
Net Income / (Loss) Continuing Operations	-53	-60	-87	-106	-91	-96
Total Pre-Tax Income	-53	-60	-87	-106	-91	-95
Total Operating Income	-48	-54	-81	-109	-97	-104
Total Gross Profit	-1.26	16	37	71	137	196
Total Revenue	7.72	34	75	136	224	308
Operating Revenue	-	34	75	136	224	308
Total Cost of Revenue	8.97	19	38	65	87	112
Operating Cost of Revenue	8.97	19	38	65	87	112
Total Operating Expenses	47	70	118	180	234	300
Selling, General & Admin Expense	30	51	89	132	171	229
Research & Development Expense	16	19	29	48	62	71
Total Other Income / (Expense), net	-5.22	-5.69	-6.43	3.35	5.57	8.48
Interest Expense	5.26	5.81	8.44	4.00	4.18	3.59
Other Income / (Expense), net	0.04	0.12	2.01	7.35	9.75	12
Income Tax Expense	-	-	-	0.08	0.37	0.19
Basic Earnings per Share	($14.47)	($3.63)	($1.96)	($2.24)	($1.75)	($1.72)
Weighted Average Basic Shares Outstanding	3.66M	16.48M	44.40M	47.26M	52.13M	55.54M
Diluted Earnings per Share	($14.47)	($3.63)	($1.96)	($2.24)	($1.75)	($1.72)
Weighted Average Diluted Shares Outstanding	3.66M	16.48M	44.40M	47.26M	52.13M	55.54M
Weighted Average Basic & Diluted Shares Outstanding	-	43.99M	44.87M	50.96M	54.82M	56.39M

This table shows PROCEPT BioRobotics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-25	-28	-26	-26	-21	-19	-25	-20	-21	-30	-32
Consolidated Net Income / (Loss)	-25	-28	-26	-26	-21	-19	-25	-20	-21	-30	-32
Net Income / (Loss) Continuing Operations	-25	-28	-26	-26	-21	-19	-25	-20	-21	-30	-32
Total Pre-Tax Income	-25	-28	-26	-26	-21	-19	-25	-20	-21	-30	-32
Total Operating Income	-26	-30	-28	-27	-22	-20	-27	-22	-23	-31	-33
Total Gross Profit	19	21	25	31	37	44	44	52	54	46	54
Total Revenue	35	44	45	53	58	68	69	79	83	76	83
Operating Revenue	35	44	45	53	58	68	69	79	83	76	83
Total Cost of Revenue	16	22	20	22	21	25	25	27	29	30	29
Operating Cost of Revenue	16	22	20	22	21	25	25	27	29	30	29
Total Operating Expenses	44	51	53	58	59	63	72	74	77	77	87
Selling, General & Admin Expense	33	36	40	41	43	48	55	56	59	58	65
Research & Development Expense	12	14	13	18	17	15	16	18	18	19	21
Total Other Income / (Expense), net	0.99	2.05	1.69	1.20	1.45	0.85	2.65	2.61	1.78	1.38	0.93
Interest Expense	1.02	1.13	1.05	1.03	1.14	0.97	0.88	0.90	0.92	0.90	0.82
Other Income / (Expense), net	2.01	3.18	2.74	2.23	2.59	1.82	3.53	3.51	2.70	2.28	1.74
Income Tax Expense	-	-	-	-	-	-	-0.05	-	-	-	-0.04
Basic Earnings per Share	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)	($0.35)	($0.38)	($0.54)	($0.56)
Weighted Average Basic Shares Outstanding	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M	55.45M	55.73M	55.54M	56.51M
Diluted Earnings per Share	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)	($0.35)	($0.38)	($0.54)	($0.56)
Weighted Average Diluted Shares Outstanding	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M	55.45M	55.73M	55.54M	56.51M
Weighted Average Basic & Diluted Shares Outstanding	50.50M	50.96M	51.42M	51.93M	52.18M	54.82M	55.33M	55.64M	55.88M	56.39M	56.92M

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	58	204	-79	35	77	-47
Net Cash From Operating Activities	-48	-57	-80	-108	-99	-49
Net Cash From Continuing Operating Activities	-48	-57	-80	-108	-99	-49
Net Income / (Loss) Continuing Operations	-53	-60	-87	-106	-91	-96
Consolidated Net Income / (Loss)	-53	-60	-87	-106	-91	-96
Depreciation Expense	2.86	-	2.84	3.81	5.23	6.39
Non-Cash Adjustments To Reconcile Net Income	2.30	3.90	15	25	37	48
Changes in Operating Assets and Liabilities, net	-0.48	-4.71	-11	-31	-50	-7.84
Net Cash From Investing Activities	-0.23	-0.59	-2.65	-25	-4.41	-9.36
Net Cash From Continuing Investing Activities	-0.23	-0.59	-2.65	-25	-4.41	-9.36
Purchase of Property, Plant & Equipment	-0.23	-0.59	-2.65	-25	-4.41	-9.36
Net Cash From Financing Activities	107	262	3.61	168	180	11
Net Cash From Continuing Financing Activities	107	262	3.61	168	180	11
Issuance of Debt	25	0.00	54	3.61	4.53	6.36
Issuance of Common Equity	0.00	172	0.00	162	165	0.00
Other Financing Activities, net	5.60	5.04	1.01	2.48	11	4.83
Effect of Exchange Rate Changes	-	-	-	0.00	0.00	-0.07
Cash Interest Paid	3.97	4.75	4.29	4.06	3.97	3.46

This table details how cash moves in and out of PROCEPT BioRobotics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	137	-31	-32	-11	-17	137	-18	-13	-8.44	-7.78	-41
Net Cash From Operating Activities	-19	-25	-32	-16	-19	-32	-17	-15	-6.64	-10	-38
Net Cash From Continuing Operating Activities	-19	-25	-32	-16	-19	-32	-17	-15	-6.64	-10	-38
Net Income / (Loss) Continuing Operations	-25	-28	-26	-26	-21	-19	-25	-20	-21	-30	-32
Consolidated Net Income / (Loss)	-25	-28	-26	-26	-21	-19	-25	-20	-21	-30	-32
Depreciation Expense	1.05	1.32	1.18	1.27	1.33	1.45	1.48	1.59	1.62	1.71	1.74
Non-Cash Adjustments To Reconcile Net Income	5.72	4.87	8.76	8.80	9.25	7.38	11	12	15	9.79	14
Changes in Operating Assets and Liabilities, net	-1.09	-3.48	-16	-0.18	-8.40	-22	-4.33	-9.50	-2.03	8.02	-22
Net Cash From Investing Activities	-5.78	-8.72	-1.95	-1.04	-0.25	-1.17	-1.84	-2.80	-2.87	-1.85	-2.91
Net Cash From Continuing Investing Activities	-5.78	-8.72	-1.95	-1.04	-0.25	-1.17	-1.84	-2.80	-2.87	-1.85	-2.91
Purchase of Property, Plant & Equipment	-5.78	-8.72	-1.95	-1.04	-0.25	-1.17	-1.84	-2.80	-2.87	-1.85	-2.91
Net Cash From Financing Activities	162	2.87	2.59	5.30	1.72	171	1.30	4.38	1.08	4.44	0.22
Net Cash From Continuing Financing Activities	162	2.87	2.59	5.30	1.72	171	1.30	4.38	1.08	4.44	0.22
Other Financing Activities, net	0.41	0.97	2.59	3.17	1.72	3.60	1.30	0.87	1.08	1.58	0.22
Effect of Exchange Rate Changes	-	-	-	-	-	-	0.00	-	-0.01	-0.04	-0.04
Cash Interest Paid	0.99	1.00	1.00	1.03	1.01	0.92	0.89	0.87	0.88	0.83	0.80

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	126	337	309	405	534	508
Total Current Assets	110	326	273	351	482	450
Cash & Equivalents	100	304	222	257	334	287
Accounts Receivable	1.55	4.46	15	48	83	84
Inventories, net	6.92	13	29	40	56	71
Prepaid Expenses	1.65	4.24	6.18	5.21	8.45	9.65
Plant, Property, & Equipment, net	8.27	5.05	8.66	29	27	30
Total Noncurrent Assets	7.44	5.81	28	25	25	27
Goodwill	2.02	1.75	1.48	1.20	0.93	0.71
Other Noncurrent Operating Assets	5.42	4.06	27	24	25	27
Total Liabilities & Shareholders' Equity	126	337	309	405	534	508
Total Liabilities	65	70	112	124	132	142
Total Current Liabilities	15	16	35	46	53	66
Accounts Payable	1.24	2.03	9.39	13	10	17
Accrued Expenses	4.64	6.48	13	17	22	23
Current Deferred Revenue	0.23	1.03	2.86	5.66	9.57	13
Other Current Liabilities	3.86	6.71	9.60	9.89	12	12
Total Noncurrent Liabilities	50	54	77	78	79	76
Long-Term Debt	44	50	51	51	51	52
Other Noncurrent Operating Liabilities	6.08	3.69	26	27	27	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-183	267	197	281	402	366
Total Preferred & Common Equity	-183	267	197	281	402	366
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-183	267	197	281	402	366
Common Stock	19	529	546	735	948	1,007
Retained Earnings	-202	-262	-349	-455	-546	-642
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.05	-0.01	0.08	0.11	0.04

This table presents PROCEPT BioRobotics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	324	284	272	421	383	374	374	519	513	512	487
Total Current Assets	289	246	230	369	329	322	323	466	458	455	428
Cash & Equivalents	249	181	150	287	226	214	197	316	303	294	246
Accounts Receivable	13	21	33	35	56	59	69	79	81	85	96
Inventories, net	22	39	43	42	42	44	51	62	67	67	78
Prepaid Expenses	4.52	4.26	3.74	3.98	5.91	5.02	6.32	7.99	7.50	9.25	8.47
Plant, Property, & Equipment, net	5.12	12	16	27	28	28	27	28	29	30	32
Total Noncurrent Assets	30	27	26	25	25	25	25	25	26	27	27
Goodwill	1.55	1.41	1.34	1.27	1.14	1.07	1.00	0.86	0.80	0.73	0.64
Other Noncurrent Operating Assets	28	26	25	24	24	24	24	25	26	26	27
Total Liabilities & Shareholders' Equity	324	284	272	421	383	374	374	519	513	512	487
Total Liabilities	103	111	117	122	119	123	133	130	127	131	139
Total Current Liabilities	27	33	36	41	39	43	54	52	50	54	64
Short-Term Debt	2.47	3.00	-	-	1.70	-	-	1.98	-	-	2.36
Accounts Payable	6.33	10	10	14	10	9.95	15	15	12	11	19
Accrued Expenses	10	7.41	9.95	13	11	15	19	15	16	22	18
Current Deferred Revenue	2.34	3.94	4.72	5.01	5.86	6.55	7.99	9.80	9.89	11	14
Other Current Liabilities	5.93	7.81	11	9.49	9.54	11	12	10	12	10	10
Total Noncurrent Liabilities	76	79	81	80	80	80	79	78	78	77	76
Long-Term Debt	51	51	51	51	51	51	51	51	52	52	52
Other Noncurrent Operating Liabilities	25	28	29	29	29	28	28	27	26	26	24
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	221	173	156	299	264	252	241	389	386	380	348
Total Preferred & Common Equity	221	173	156	299	264	252	241	389	386	380	348
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	221	173	156	299	264	252	241	389	386	380	348
Common Stock	541	550	558	726	744	758	768	960	976	992	1,021
Retained Earnings	-321	-377	-402	-427	-481	-506	-527	-571	-590	-612	-673
Accumulated Other Comprehensive Income / (Loss)	0.22	0.02	-0.01	-0.01	0.11	-0.00	-0.02	0.22	-0.14	0.04	-0.02

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	346.72%	117.60%	81.55%	64.84%	37.22%
EBITDA Growth	0.00%	-12.96%	-49.59%	-29.29%	16.41%	-4.63%
EBIT Growth	0.00%	-13.16%	-45.65%	-29.46%	14.40%	-5.68%
NOPAT Growth	0.00%	-13.31%	-49.04%	-35.24%	11.50%	-7.50%
Net Income Growth	0.00%	-12.89%	-45.61%	-21.51%	13.68%	-4.55%
EPS Growth	0.00%	74.91%	46.01%	-14.29%	21.88%	1.71%
Operating Cash Flow Growth	0.00%	-18.60%	-40.20%	-34.36%	8.14%	50.63%
Free Cash Flow Firm Growth	0.00%	0.00%	-69.63%	-81.09%	10.28%	25.74%
Invested Capital Growth	0.00%	30.52%	100.78%	191.90%	60.24%	9.18%
Revenue Q/Q Growth	0.00%	0.00%	22.22%	17.02%	12.34%	2.72%
EBITDA Q/Q Growth	0.00%	0.00%	-6.01%	1.48%	14.34%	-14.20%
EBIT Q/Q Growth	0.00%	0.00%	-9.98%	-2.34%	8.87%	-13.44%
NOPAT Q/Q Growth	0.00%	0.00%	-11.32%	-4.32%	9.25%	-12.24%
Net Income Q/Q Growth	0.00%	0.00%	-12.70%	0.63%	8.64%	-12.99%
EPS Q/Q Growth	0.00%	0.00%	-229.80%	3.86%	10.26%	-13.16%
Operating Cash Flow Q/Q Growth	0.00%	-5.58%	-12.13%	0.35%	-8.29%	31.05%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-12.84%	-4.75%	21.35%
Invested Capital Q/Q Growth	0.00%	0.00%	3.80%	19.22%	25.10%	-4.78%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	-16.26%	46.02%	49.44%	52.17%	61.07%	63.70%
EBITDA Margin	-581.81%	-147.13%	-101.14%	-72.03%	-36.52%	-27.72%
Operating Margin	-619.44%	-157.12%	-107.61%	-80.16%	-43.04%	-33.71%
EBIT Margin	-618.87%	-156.77%	-104.93%	-74.82%	-38.86%	-29.80%
Profit (Net Income) Margin	-687.04%	-173.62%	-116.18%	-77.76%	-40.72%	-31.02%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.20%
Interest Burden Percent	111.02%	110.75%	110.72%	103.92%	104.80%	103.91%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-341.86%	-336.08%	-294.12%	-152.05%	-69.42%	-57.94%
ROIC Less NNEP Spread (ROIC-NNEP)	-303.64%	-321.72%	-279.73%	-136.42%	-59.68%	-49.10%
Return on Net Nonoperating Assets (RNNOA)	254.89%	299.59%	256.57%	107.73%	42.65%	33.06%
Return on Equity (ROE)	-86.97%	-36.49%	-37.55%	-44.32%	-26.77%	-24.89%
Cash Return on Invested Capital (CROIC)	0.00%	-362.56%	-361.13%	-249.98%	-115.72%	-66.72%
Operating Return on Assets (OROA)	-37.91%	-23.35%	-24.36%	-28.54%	-18.58%	-17.62%
Return on Assets (ROA)	-42.09%	-25.85%	-26.97%	-29.66%	-19.48%	-18.34%
Return on Common Equity (ROCE)	260.94%	-9.37%	-37.55%	-44.32%	-26.77%	-24.89%
Return on Equity Simple (ROE_SIMPLE)	28.99%	-22.41%	-44.22%	-37.72%	-22.73%	0.00%
Net Operating Profit after Tax (NOPAT)	-33	-38	-57	-76	-68	-73
NOPAT Margin	-433.61%	-109.98%	-75.33%	-56.11%	-30.12%	-23.60%
Net Nonoperating Expense Percent (NNEP)	-38.22%	-14.36%	-14.40%	-15.63%	-9.74%	-8.85%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-22.76%	-23.01%	-14.91%	-17.41%
Cost of Revenue to Revenue	116.26%	53.98%	50.56%	47.83%	38.93%	36.30%
SG&A Expenses to Revenue	392.28%	148.05%	118.42%	96.76%	76.35%	74.28%
R&D to Revenue	210.90%	55.10%	38.63%	35.57%	27.75%	23.14%
Operating Expenses to Revenue	603.17%	203.14%	157.05%	132.33%	104.10%	97.41%
Earnings before Interest and Taxes (EBIT)	-48	-54	-79	-102	-87	-92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-45	-51	-76	-98	-82	-85
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	4.07	9.43	7.54	10.45	4.80
Price to Tangible Book Value (P/TBV)	0.00	4.10	9.50	7.57	10.47	4.81
Price to Revenue (P/Rev)	17.82	31.56	24.76	15.54	18.72	5.71
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	33.73	65.25	65.74	25.52	32.67	11.63
Enterprise Value to Revenue (EV/Rev)	42.79	24.18	22.48	14.03	17.46	4.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.80	0.19	0.26	0.18	0.13	0.14
Long-Term Debt to Equity	0.73	0.19	0.26	0.18	0.13	0.14
Financial Leverage	-0.84	-0.93	-0.92	-0.79	-0.71	-0.67
Leverage Ratio	2.07	1.41	1.39	1.49	1.37	1.36
Compound Leverage Factor	2.29	1.56	1.54	1.55	1.44	1.41
Debt to Total Capital	44.54%	15.77%	20.63%	15.46%	11.35%	12.36%
Short-Term Debt to Total Capital	4.14%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	40.40%	15.77%	20.63%	15.46%	11.35%	12.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	221.85%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-166.39%	84.23%	79.37%	84.54%	88.65%	87.64%
Debt to EBITDA	-1.09	-0.99	-0.68	-0.52	-0.63	-0.60
Net Debt to EBITDA	1.14	5.01	2.26	2.10	3.44	2.75
Long-Term Debt to EBITDA	-0.99	-0.99	-0.68	-0.52	-0.63	-0.60
Debt to NOPAT	-1.46	-1.32	-0.91	-0.67	-0.76	-0.71
Net Debt to NOPAT	1.53	6.71	3.03	2.69	4.17	3.23
Long-Term Debt to NOPAT	-1.33	-1.32	-0.91	-0.67	-0.76	-0.71
Altman Z-Score	-1.25	8.92	8.67	9.08	18.54	6.57
Noncontrolling Interest Sharing Ratio	400.02%	74.33%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	7.59	20.08	7.73	7.63	9.07	6.85
Quick Ratio	7.00	19.01	6.72	6.65	7.85	5.62
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-41	-69	-126	-113	-84
Operating Cash Flow to CapEx	-20,748.07%	-9,684.80%	-3,029.85%	-428.48%	-2,250.24%	-523.57%
Free Cash Flow to Firm to Interest Expense	0.00	-7.04	-8.22	-31.45	-26.94	-23.35
Operating Cash Flow to Interest Expense	-9.19	-9.87	-9.52	-27.03	-23.71	-13.66
Operating Cash Flow Less CapEx to Interest Expense	-9.23	-9.97	-9.84	-33.34	-24.77	-16.27
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.06	0.15	0.23	0.38	0.48	0.59
Accounts Receivable Turnover	4.98	11.47	7.60	4.28	3.40	3.69
Inventory Turnover	1.30	1.85	1.82	1.91	1.82	1.76
Fixed Asset Turnover	0.93	5.18	10.95	7.28	8.10	10.79
Accounts Payable Turnover	7.24	11.38	6.64	5.69	7.43	8.19
Days Sales Outstanding (DSO)	73.26	31.83	48.02	85.29	107.20	98.95
Days Inventory Outstanding (DIO)	281.68	196.85	200.60	191.34	200.30	207.04
Days Payable Outstanding (DPO)	50.45	32.06	54.95	64.13	49.14	44.58
Cash Conversion Cycle (CCC)	304.50	196.62	193.66	212.51	258.37	261.41
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	9.79	13	26	75	120	131
Invested Capital Turnover	0.79	3.06	3.90	2.71	2.30	2.46
Increase / (Decrease) in Invested Capital	0.00	2.99	13	49	45	11
Enterprise Value (EV)	330	834	1,686	1,911	3,920	1,523
Market Capitalization	138	1,088	1,858	2,116	4,202	1,758
Book Value per Share	($49.93)	$6.14	$4.41	$5.56	$7.71	$6.55
Tangible Book Value per Share	($50.48)	$6.10	$4.37	$5.54	$7.69	$6.53
Total Capital	110	317	248	332	454	417
Total Debt	49	50	51	51	51	52
Total Long-Term Debt	44	50	51	51	51	52
Net Debt	-51	-254	-171	-206	-282	-235
Capital Expenditures (CapEx)	0.23	0.59	2.65	25	4.41	9.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.15	5.61	15	47	95	98
Debt-free Net Working Capital (DFNWC)	100	310	237	305	429	385
Net Working Capital (NWC)	96	310	237	305	429	385
Net Nonoperating Expense (NNE)	20	22	31	29	24	23
Net Nonoperating Obligations (NNO)	-51	-254	-171	-206	-282	-235
Total Depreciation and Amortization (D&A)	2.86	3.32	2.84	3.81	5.23	6.39
Debt-free, Cash-free Net Working Capital to Revenue	1.96%	16.28%	19.60%	34.82%	42.31%	31.84%
Debt-free Net Working Capital to Revenue	1,299.48%	899.05%	316.39%	223.69%	190.96%	124.84%
Net Working Capital to Revenue	1,240.51%	899.05%	316.39%	223.69%	190.96%	124.84%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($3.63)	($1.96)	($2.24)	($1.75)	($1.72)
Adjusted Weighted Average Basic Shares Outstanding	0.00	16.48M	44.40M	47.26M	52.13M	55.54M
Adjusted Diluted Earnings per Share	$0.00	($3.63)	($1.96)	($2.24)	($1.75)	($1.72)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	16.48M	44.40M	47.26M	52.13M	55.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	43.99M	44.87M	50.96M	54.82M	56.39M
Normalized Net Operating Profit after Tax (NOPAT)	-33	-38	-57	-76	-68	-73
Normalized NOPAT Margin	-433.61%	-109.98%	-75.33%	-56.11%	-30.12%	-23.60%
Pre Tax Income Margin	-687.04%	-173.62%	-116.18%	-77.76%	-40.72%	-30.96%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-9.08	-9.30	-9.33	-25.51	-20.85	-25.60
NOPAT to Interest Expense	-6.36	-6.53	-6.69	-19.13	-16.16	-20.27
EBIT Less CapEx to Interest Expense	-9.12	-9.40	-9.64	-31.82	-21.90	-28.21
NOPAT Less CapEx to Interest Expense	-6.40	-6.63	-7.01	-25.44	-17.22	-22.88
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from PROCEPT BioRobotics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	56,390,196.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	56,390,196.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.56
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	72.50%	83.29%	82.51%	61.17%	66.29%	56.57%	55.28%	48.41%	42.76%	11.94%	20.20%
EBITDA Growth	-10.24%	-7.18%	11.48%	1.48%	17.93%	34.43%	5.66%	26.72%	-1.99%	-68.38%	-29.85%
EBIT Growth	-11.56%	-9.70%	9.73%	-1.13%	15.97%	32.20%	4.22%	24.04%	-3.32%	-64.17%	-29.10%
NOPAT Growth	-15.85%	-18.05%	2.57%	-4.69%	12.43%	33.32%	0.76%	17.29%	-3.41%	-57.48%	-18.84%
Net Income Growth	-8.88%	2.36%	8.87%	-1.35%	14.82%	31.45%	4.70%	23.60%	-2.08%	-58.28%	-27.90%
EPS Growth	0.00%	14.29%	19.05%	10.71%	21.57%	37.04%	11.76%	30.00%	5.00%	-58.82%	-24.44%
Operating Cash Flow Growth	4.57%	1.51%	10.14%	44.47%	0.75%	-30.65%	47.41%	4.40%	64.71%	68.12%	-124.54%
Free Cash Flow Firm Growth	-103.00%	-129.96%	-39.60%	2.55%	12.89%	15.76%	17.14%	-19.32%	-18.67%	44.40%	3.06%
Invested Capital Growth	154.14%	191.90%	100.68%	57.10%	52.70%	60.24%	38.11%	51.09%	43.45%	9.18%	23.43%
Revenue Q/Q Growth	6.04%	24.16%	2.20%	19.79%	9.40%	16.90%	1.36%	14.49%	5.23%	-8.33%	8.84%
EBITDA Q/Q Growth	4.77%	-11.15%	10.06%	1.69%	20.67%	11.20%	-36.21%	23.63%	-10.41%	-43.33%	-7.67%
EBIT Q/Q Growth	2.95%	-11.77%	5.57%	1.27%	19.36%	9.82%	-33.39%	21.70%	-9.68%	-40.35%	-7.31%
NOPAT Q/Q Growth	0.06%	-15.42%	6.46%	2.97%	16.40%	12.11%	-39.21%	19.13%	-4.52%	-33.84%	-5.05%
Net Income Q/Q Growth	2.62%	-11.71%	5.63%	1.28%	18.15%	10.10%	-31.19%	20.86%	-9.36%	-39.40%	-6.00%
EPS Q/Q Growth	8.93%	-5.88%	5.56%	1.96%	20.00%	15.00%	-32.35%	22.22%	-8.57%	-42.11%	-3.70%
Operating Cash Flow Q/Q Growth	33.16%	-30.88%	-30.22%	51.26%	-19.47%	-72.29%	47.58%	11.41%	55.89%	-55.64%	-269.20%
Free Cash Flow Firm Q/Q Growth	-6.70%	-24.81%	6.62%	21.63%	4.63%	-20.70%	8.15%	-12.85%	5.15%	43.45%	-60.16%
Invested Capital Q/Q Growth	10.74%	19.22%	22.27%	-2.68%	7.64%	25.10%	5.39%	6.46%	2.20%	-4.78%	19.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	53.77%	48.77%	56.21%	59.01%	63.24%	64.00%	63.85%	65.35%	64.81%	60.63%	64.89%
EBITDA Margin	-64.24%	-57.51%	-53.27%	-43.72%	-31.70%	-24.08%	-32.37%	-21.59%	-22.65%	-35.42%	-35.04%
Operating Margin	-72.96%	-67.83%	-62.08%	-50.28%	-38.42%	-28.89%	-39.67%	-28.02%	-27.83%	-40.64%	-39.22%
EBIT Margin	-67.24%	-60.53%	-55.93%	-46.10%	-33.98%	-26.21%	-34.50%	-23.60%	-24.59%	-37.65%	-37.13%
Profit (Net Income) Margin	-70.14%	-63.11%	-58.28%	-48.03%	-35.93%	-27.63%	-35.77%	-24.73%	-25.70%	-39.07%	-38.06%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.64%	99.86%
Interest Burden Percent	104.32%	104.26%	104.19%	104.19%	105.75%	105.42%	103.68%	104.79%	104.48%	103.11%	102.65%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-135.84%	-128.65%	-99.05%	-85.26%	-67.74%	-46.60%	-63.48%	-48.22%	-50.06%	-69.84%	-62.60%
ROIC Less NNEP Spread (ROIC-NNEP)	-132.75%	-125.04%	-94.65%	-80.03%	-64.98%	-44.52%	-60.94%	-46.27%	-47.39%	-66.70%	-58.72%
Return on Net Nonoperating Assets (RNNOA)	110.41%	98.74%	64.96%	51.41%	45.90%	31.82%	40.60%	30.03%	29.59%	44.91%	36.21%
Return on Equity (ROE)	-25.43%	-29.92%	-34.10%	-33.85%	-21.84%	-14.77%	-22.88%	-18.19%	-20.47%	-24.93%	-26.39%
Cash Return on Invested Capital (CROIC)	-254.48%	-249.98%	-177.66%	-149.70%	-135.63%	-115.72%	-93.93%	-98.12%	-91.18%	-66.72%	-75.00%
Operating Return on Assets (OROA)	-21.00%	-23.09%	-26.20%	-25.17%	-17.08%	-12.54%	-19.05%	-14.62%	-16.65%	-22.26%	-23.76%
Return on Assets (ROA)	-21.91%	-24.08%	-27.30%	-26.22%	-18.06%	-13.22%	-19.75%	-15.32%	-17.40%	-23.10%	-24.35%
Return on Common Equity (ROCE)	-25.43%	-29.92%	-34.10%	-33.85%	-21.84%	-14.77%	-22.88%	-18.19%	-20.47%	-24.93%	-26.39%
Return on Equity Simple (ROE_SIMPLE)	-35.60%	0.00%	-39.15%	-41.19%	-41.48%	0.00%	-23.18%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-21	-19	-19	-16	-14	-19	-16	-16	-22	-23
NOPAT Margin	-51.07%	-47.48%	-43.45%	-35.20%	-26.90%	-20.22%	-27.77%	-19.62%	-19.48%	-28.45%	-27.46%
Net Nonoperating Expense Percent (NNEP)	-3.10%	-3.61%	-4.40%	-5.23%	-2.76%	-2.07%	-2.54%	-1.96%	-2.67%	-3.14%	-3.88%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.23%	-	-	-	-3.04%	-4.34%	-3.55%	-3.76%	-5.20%	-5.68%
Cost of Revenue to Revenue	46.23%	51.23%	43.79%	40.99%	36.76%	36.00%	36.15%	34.65%	35.19%	39.37%	35.11%
SG&A Expenses to Revenue	93.68%	83.33%	88.91%	76.49%	73.14%	70.81%	79.81%	71.11%	70.82%	76.32%	78.29%
R&D to Revenue	33.05%	33.26%	29.38%	32.80%	28.52%	22.08%	23.72%	22.27%	21.83%	24.95%	25.82%
Operating Expenses to Revenue	126.73%	116.60%	118.29%	109.29%	101.66%	92.89%	103.52%	93.37%	92.64%	101.27%	104.12%
Earnings before Interest and Taxes (EBIT)	-24	-26	-25	-25	-20	-18	-24	-19	-20	-29	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-23	-25	-24	-23	-19	-16	-22	-17	-19	-27	-29
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.96	7.54	9.45	12.48	17.25	10.45	8.21	8.26	5.22	4.80	4.06
Price to Tangible Book Value (P/TBV)	4.98	7.57	9.49	12.53	17.32	10.47	8.23	8.28	5.23	4.81	4.06
Price to Revenue (P/Rev)	12.76	15.54	15.96	17.79	20.82	18.72	12.82	11.59	6.62	5.71	4.38
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.89	25.52	25.38	33.44	41.87	32.67	23.18	21.81	12.67	11.63	7.81
Enterprise Value to Revenue (EV/Rev)	10.73	14.03	14.86	16.87	20.09	17.46	11.77	10.68	5.81	4.94	3.78
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.17	0.18	0.20	0.20	0.21	0.13	0.14	0.13	0.14	0.14	0.16
Long-Term Debt to Equity	0.17	0.18	0.19	0.20	0.21	0.13	0.13	0.13	0.14	0.14	0.15
Financial Leverage	-0.83	-0.79	-0.69	-0.64	-0.71	-0.71	-0.67	-0.65	-0.62	-0.67	-0.62
Leverage Ratio	1.43	1.49	1.53	1.59	1.47	1.37	1.38	1.39	1.43	1.36	1.37
Compound Leverage Factor	1.49	1.56	1.59	1.65	1.56	1.45	1.43	1.46	1.49	1.40	1.40
Debt to Total Capital	14.63%	15.46%	16.74%	16.95%	17.58%	11.35%	12.08%	11.78%	11.94%	12.36%	13.45%
Short-Term Debt to Total Capital	0.00%	0.00%	0.54%	0.00%	0.00%	0.00%	0.45%	0.00%	0.00%	0.00%	0.59%
Long-Term Debt to Total Capital	14.63%	15.46%	16.20%	16.95%	17.58%	11.35%	11.63%	11.78%	11.94%	12.36%	12.86%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	85.37%	84.54%	83.26%	83.05%	82.42%	88.65%	87.92%	88.22%	88.06%	87.64%	86.55%
Debt to EBITDA	-0.52	-0.52	-0.53	-0.52	-0.54	-0.63	-0.66	-0.69	-0.69	-0.60	-0.59
Net Debt to EBITDA	2.38	2.10	1.74	1.64	1.52	3.44	3.26	3.38	3.25	2.75	2.08
Long-Term Debt to EBITDA	-0.52	-0.52	-0.52	-0.52	-0.54	-0.63	-0.64	-0.69	-0.69	-0.60	-0.56
Debt to NOPAT	-0.70	-0.67	-0.70	-0.67	-0.69	-0.76	-0.79	-0.80	-0.80	-0.71	-0.71
Net Debt to NOPAT	3.23	2.69	2.27	2.12	1.95	4.17	3.89	3.91	3.75	3.23	2.51
Long-Term Debt to NOPAT	-0.70	-0.67	-0.68	-0.67	-0.69	-0.76	-0.76	-0.80	-0.80	-0.71	-0.68
Altman Z-Score	6.92	9.70	11.95	14.63	18.03	18.97	14.46	14.79	8.80	6.98	5.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.91	7.63	8.52	7.51	6.02	9.07	8.95	9.21	8.44	6.85	6.73
Quick Ratio	7.78	6.65	7.29	6.37	4.95	7.85	7.60	7.71	7.03	5.62	5.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-56	-70	-65	-51	-49	-59	-54	-61	-58	-33	-52
Operating Cash Flow to CapEx	-327.73%	-284.49%	-1,659.10%	-1,508.72%	-7,642.28%	-2,759.03%	-924.84%	-536.87%	-231.35%	-558.22%	-1,308.41%
Free Cash Flow to Firm to Interest Expense	-54.97	-62.14	-62.47	-49.67	-42.80	-60.78	-61.68	-68.21	-63.00	-36.58	-64.11
Operating Cash Flow to Interest Expense	-18.59	-22.04	-30.90	-15.28	-16.49	-33.43	-19.36	-16.81	-7.22	-11.54	-46.61
Operating Cash Flow Less CapEx to Interest Expense	-24.26	-29.78	-32.76	-16.29	-16.71	-34.64	-21.46	-19.94	-10.34	-13.61	-50.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.38	0.47	0.55	0.50	0.48	0.55	0.62	0.68	0.59	0.64
Accounts Receivable Turnover	4.90	4.28	4.08	3.83	3.86	3.40	3.68	3.94	3.91	3.69	3.67
Inventory Turnover	1.73	1.91	1.81	1.85	1.83	1.82	1.79	1.78	1.81	1.76	1.66
Fixed Asset Turnover	7.24	7.28	7.73	8.02	7.45	8.10	8.80	9.77	10.59	10.79	10.76
Accounts Payable Turnover	5.61	5.69	7.12	8.00	5.94	7.43	7.46	9.06	8.11	8.19	6.89
Days Sales Outstanding (DSO)	74.42	85.29	89.57	95.18	94.67	107.20	99.15	92.75	93.44	98.95	99.55
Days Inventory Outstanding (DIO)	210.71	191.34	202.11	197.50	199.41	200.30	204.22	205.55	201.80	207.04	220.03
Days Payable Outstanding (DPO)	65.04	64.13	51.25	45.63	61.47	49.14	48.94	40.28	44.98	44.58	52.98
Cash Conversion Cycle (CCC)	220.08	212.51	240.43	247.05	232.61	258.37	254.44	258.02	250.26	261.41	266.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	63	75	92	89	96	120	126	135	138	131	156
Invested Capital Turnover	2.66	2.71	2.28	2.42	2.52	2.30	2.29	2.46	2.57	2.46	2.28
Increase / (Decrease) in Invested Capital	38	49	46	32	33	45	35	46	42	11	30
Enterprise Value (EV)	1,249	1,911	2,323	2,979	4,015	3,920	2,931	2,936	1,743	1,523	1,219
Market Capitalization	1,486	2,116	2,496	3,142	4,161	4,202	3,194	3,187	1,986	1,758	1,410
Book Value per Share	$6.61	$5.56	$5.18	$4.88	$4.64	$7.71	$7.10	$6.97	$6.84	$6.55	$6.17
Tangible Book Value per Share	$6.58	$5.54	$5.15	$4.86	$4.63	$7.69	$7.08	$6.96	$6.82	$6.53	$6.15
Total Capital	351	332	317	303	293	454	443	437	432	417	402
Total Debt	51	51	53	51	51	51	53	52	52	52	54
Total Long-Term Debt	51	51	51	51	51	51	51	52	52	52	52
Net Debt	-237	-206	-173	-163	-145	-282	-263	-251	-243	-235	-192
Capital Expenditures (CapEx)	5.78	8.72	1.95	1.04	0.25	1.17	1.84	2.80	2.87	1.85	2.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)	39	47	67	65	73	95	100	106	107	98	121
Debt-free Net Working Capital (DFNWC)	327	305	292	279	269	429	416	408	401	385	367
Net Working Capital (NWC)	327	305	291	279	269	429	414	408	401	385	364
Net Nonoperating Expense (NNE)	6.70	6.81	6.60	6.85	5.28	5.06	5.53	4.05	5.18	8.12	8.81
Net Nonoperating Obligations (NNO)	-237	-206	-173	-163	-145	-282	-263	-251	-243	-235	-192
Total Depreciation and Amortization (D&A)	1.05	1.32	1.18	1.27	1.33	1.45	1.48	1.59	1.62	1.71	1.74
Debt-free, Cash-free Net Working Capital to Revenue	33.89%	34.82%	42.64%	36.79%	36.32%	42.31%	39.94%	38.42%	35.54%	31.84%	37.61%
Debt-free Net Working Capital to Revenue	281.23%	223.69%	186.94%	158.03%	134.77%	190.96%	166.87%	148.51%	133.66%	124.84%	113.89%
Net Working Capital to Revenue	281.23%	223.69%	185.85%	158.03%	134.77%	190.96%	166.07%	148.51%	133.66%	124.84%	113.16%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)	($0.35)	($0.38)	($0.54)	($0.56)
Adjusted Weighted Average Basic Shares Outstanding	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M	55.45M	55.73M	55.54M	56.51M
Adjusted Diluted Earnings per Share	($0.51)	($0.54)	($0.51)	($0.50)	($0.40)	($0.34)	($0.45)	($0.35)	($0.38)	($0.54)	($0.56)
Adjusted Weighted Average Diluted Shares Outstanding	48.31M	47.26M	51.01M	51.62M	52.01M	52.13M	54.92M	55.45M	55.73M	55.54M	56.51M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.50M	50.96M	51.42M	51.93M	52.18M	54.82M	55.33M	55.64M	55.88M	56.39M	56.92M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-21	-19	-19	-16	-14	-19	-16	-16	-22	-23
Normalized NOPAT Margin	-51.07%	-47.48%	-43.45%	-35.20%	-26.90%	-20.22%	-27.77%	-19.62%	-19.48%	-28.45%	-27.46%
Pre Tax Income Margin	-70.14%	-63.11%	-58.28%	-48.03%	-35.93%	-27.63%	-35.77%	-24.73%	-25.70%	-38.83%	-38.11%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-23.16	-23.45	-23.84	-23.88	-17.40	-18.46	-27.21	-20.87	-22.30	-32.14	-37.73
NOPAT to Interest Expense	-17.59	-18.39	-18.52	-18.23	-13.77	-14.24	-21.90	-17.35	-17.67	-24.28	-27.90
EBIT Less CapEx to Interest Expense	-28.84	-31.20	-25.70	-24.89	-17.61	-19.67	-29.30	-24.01	-25.42	-34.20	-41.29
NOPAT Less CapEx to Interest Expense	-23.26	-26.14	-20.38	-19.25	-13.99	-15.45	-23.99	-20.49	-20.79	-26.34	-31.46
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

PROCEPT BioRobotics Corp (PRCT) shows a clear top-line growth trajectory in 2024–2025, with a solid gross margin, but the company continues to operate at a net loss and burn cash. The balance sheet remains liquidity-rich, supported by a meaningful cash position and ongoing financing activity. Below are the 4-year trend highlights drawn from quarterly statements provided.

Top-line momentum in 2025: Operating revenue rose through 2025, with quarterly figures reaching about $83.3M in Q3 2025 and $76.4M in Q4 2025, indicating meaningful revenue growth during the year.
Stable gross margins: The company maintains robust gross margins in 2025 (roughly 60%–65%), with 2025 quarters showing Total Gross Profit in the mid-to-upper $40Ms on revenues of $70M–$83M.
Continued positive financing activity: Net cash from financing activities was positive in each 2025 quarter (around $1.3M to $4.4M), signaling ongoing access to capital as needed.
Strong cash position persists: Cash and equivalents remained ample in 2025, roughly in the $294M–$316M range across the year, supporting liquidity for operations and development.
Steady R&D investment: R&D spending remained steady in 2025 (roughly $16M–$19M per quarter), underscoring ongoing investment in product development.
Leverage and equity backdrop: Total equity sits in the $380M–$389M range with long-term debt around $51M in mid-2025, suggesting a modest leverage profile and a sizable equity base.
Asset growth trend: Total assets expanded to about $511M by Q3 2025, reflecting growing asset ownership alongside the business expansion.
Net income remains negative: Net income attributable to common shareholders was about -$29.8M in Q4 2025, continuing a multi-year pattern of losses despite improving quarterly dynamics earlier in 2025.
High operating costs: Total operating expenses were high in 2025 (e.g., SG&A plus R&D around $77M in Q4), contributing to a material operating loss (around $31M in Q4).
Persistent operating cash burn: Operating cash flow was negative in every 2025 quarter (CFO roughly between -$6.6M and -$16.98M), indicating ongoing cash burn despite top-line gains.

05/06/26 10:51 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About PROCEPT BioRobotics' Financials

When does PROCEPT BioRobotics' fiscal year end?

According to the most recent income statement we have on file, PROCEPT BioRobotics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has PROCEPT BioRobotics' net income changed over the last 5 years?

PROCEPT BioRobotics' net income appears to be on an upward trend, with a most recent value of -$95.57 million in 2025, rising from -$53.02 million in 2020. The previous period was -$91.41 million in 2024. See PROCEPT BioRobotics' forecast for analyst expectations on whatâ€™s next for the company.

What is PROCEPT BioRobotics' operating income?

PROCEPT BioRobotics' total operating income in 2025 was -$103.86 million, based on the following breakdown:

Total Gross Profit: $196.23 million
Total Operating Expenses: $300.09 million

How has PROCEPT BioRobotics' revenue changed over the last 5 years?

Over the last 5 years, PROCEPT BioRobotics' total revenue changed from $7.72 million in 2020 to $308.05 million in 2025, a change of 3,891.9%.

How much debt does PROCEPT BioRobotics have?

PROCEPT BioRobotics' total liabilities were at $142.21 million at the end of 2025, a 7.9% increase from 2024, and a 118.7% increase since 2020.

How much cash does PROCEPT BioRobotics have?

In the past 5 years, PROCEPT BioRobotics' cash and equivalents has ranged from $100.13 million in 2020 to $333.73 million in 2024, and is currently $286.50 million as of their latest financial filing in 2025.

How has PROCEPT BioRobotics' book value per share changed over the last 5 years?

Over the last 5 years, PROCEPT BioRobotics' book value per share changed from -49.93 in 2020 to 6.55 in 2025, a change of -113.1%.

Related Companies

Financial statements for NASDAQ:PRCT last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About PROCEPT BioRobotics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Financials

Annual Income Statements for PROCEPT BioRobotics

Quarterly Income Statements for PROCEPT BioRobotics

Annual Cash Flow Statements for PROCEPT BioRobotics

Quarterly Cash Flow Statements for PROCEPT BioRobotics

Annual Balance Sheets for PROCEPT BioRobotics

Quarterly Balance Sheets for PROCEPT BioRobotics

Annual Metrics And Ratios for PROCEPT BioRobotics

Quarterly Metrics And Ratios for PROCEPT BioRobotics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About PROCEPT BioRobotics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools